• Email Alerts
  • Careers
  • Contact Us

SCYNEXIS, Inc.

  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
    • Careers
    • Contact
  • Product
    • ibrexafungerp
    • Patent
  • Pipeline
    • Ibrexafungerp Development Pipeline
    • Clinical Trials
    • Vulvovaginal Candidiasis
    • Refractory Invasive Fungal Infections
    • Invasive Candidiasis
    • Invasive Aspergillosis
  • Science
    • SCYNEXIS Research Platform
    • Publications and Presentations
    • Expanded Access
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Data

SCYNEXIS, Inc.

You are now leaving the SCYNEXIS Corporate Website.

I understand Cancel

Press Releases

Investors

Investors

  • Overview
  • News Releases
    • Press Releases
    • Email Alerts
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Governance
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Financials & Filings
    • SEC Filings
    • Annual Reports
    • Proxy Statements
    • Quarterly Results
    • Key Ratios
  • Stock Data
    • Quote
    • Historical Data
    • Investor Calculator
    • Analyst Coverage
    • Ownership Profile
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News Releases

  • Press Releases
  • Email Alerts

BREXAFEMME® (Ibrexafungerp Tablets) Receives 2021 Popular Science Best of What’s New Award in the Health Category

Dec 1, 2021

SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6

Nov 29, 2021

SCYNEXIS Pivotal Phase 3 VANISH-306 Trial Results Published in the International Journal of Obstetrics and Gynaecology (BJOG) Demonstrate Statistical Superiority of BREXAFEMME® (Ibrexafungerp Tablets) Over Placebo for Vaginal Yeast Infection

Nov 23, 2021

SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Nov 10, 2021

SCYNEXIS Announces Successful Completion of Phase 1 Trial Evaluating Intravenous (IV) Formulation of Ibrexafungerp

Nov 9, 2021

SCYNEXIS to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 10

Nov 3, 2021

SCYNEXIS Pivotal Phase 3 VANISH-303 Trial Results Published in Clinical Infectious Diseases Demonstrate Significant Superiority of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection

Oct 21, 2021

SCYNEXIS to Present Pooled Data Analysis Results Demonstrating Consistent Efficacy and Safety Outcomes Across Two Phase 3 VANISH Clinical Trials of Oral Ibrexafungerp Therapy for Vaginal Yeast Infection at October Medical Conferences

Oct 13, 2021

SCYNEXIS Announces Preclinical Data at the 10th Trends in Medical Mycology Meeting Supporting Potential of Ibrexafungerp to Treat Mucormycosis

Oct 11, 2021

SCYNEXIS to Present Clinical Data from Ongoing FURI and CARES Studies at the 10th Trends in Medical Mycology Meeting Showing Oral Ibrexafungerp Provides a Favorable Therapeutic Response in Patients with Severe Fungal Infections

Oct 7, 2021
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...16

    1 Evertrust Plaza, Jersey City, NJ 07302
    (201) 884-5485
    View Google Map

    © 2022 SCYNEXIS, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Contact Us